Our aims were to assess risks of early rebleeding after successful endoscopic hemostasis for Forrest oozing (FIB) peptic ulcer bleeding (PUBs) compared with other stigmata of recent hemorrhage (SRH).
INTRODUCTION
Some investigators in endoscopic studies utilize the Forrest (F) classifi cation for risk stratifi cation and others use descriptive terms for stigmata of recent hemorrhage (SRH) for peptic ulcer bleeding-PUBs ( 1, 2 ) . Th e former group describes FIA (spurting or pulsatile arterial bleeding), FIB (oozing), and FIIA (nonbleeding visible vessel-NBVV) as "major SRH", based upon reported risks of peptic ulcer rebleeding (1) (2) (3) (4) . Th e fact that PUBs with both spurting bleeding and oozing are included in the fi rst major Forrest group (I) implies that this group was perceived as having a higher risk of rebleeding than the second Forrest group (II), including FIIA or FIIB patients, and this should be used as the primary means of stratifying PUBs for their rebleed risk ( 2 ) . Others also include adherent clot (FIIB) as a major stigmata ( 1, (3) (4) (5) .
Some PUB investigators include both FIA and FIB bleeding together as "active bleeding. " Th ey plan studies, estimate sample sizes, and report outcomes based upon an assumption of similarity Reassessment of Rebleeding Risk of Forrest IB (Oozing) Peptic Ulcer Bleeding in a Large International Randomized Trial of FIA and FIB rather than a signifi cant diff erence in rebleeding rates with medical and endoscopic treatments. However, FIB has been reported by some investigators to have a lower risk for PUB rebleeding than FIA ( 6, 7 ) .
A recent prospective cohort study with endoscopic Doppler endoscopic probe reported signifi cantly higher rates in detection of arterial blood fl ow underlying FIA than FIB PUBs, signifi cantly higher post hemostasis rates of residual blood fl ow, and also signifi cantly higher rebleed rates for PUB patients with FIA than FIB aft er current standard of care endoscopic hemostasis ( 8 ) . Past endoscopic randomized controlled trials (RCT's) of bleeding PUBs also previously found a lower rebleeding risk for FIB than FIA ( 6, 7, 9 ) .
In some RCT's of medical compared with endoscopic hemostasis of PUB, FIB PUBs not associated with a visible vessel or clot were considered to be a low-risk SRH for rebleeding. Th ese studies therefore excluded FIB PUB patients ( 10, 11 ) . However, in other more recent RCT's studies or a meta-analysis (12) (13) (14) , a costeff ectiveness analysis ( 15 ) , a consensus report ( 3 )m and a review on ulcer hemorrhage ( 5 ), PUBs with FIB and FIA were lumped together as "active bleeding" and considered to be one high-risk stigmata.
On basis of these data and classifi cations of SRH, there is a controversy and diff erent interpretations about the actual rebleed risks of FIB vs. FIA PUBs and whether these should be considered as similar or diff erent for risk stratifi cation, sample size determination, or clinical treatment (medically and endoscopically).
Th e purposes of this study were (i) to assess the risk factors and rates of early rebleeding for FIB (oozing) PUBs compared with other SRH aft er successful endoscopic hemostasis in a large international RCT (in the placebo treatment group), and (ii) to determine the medical treatment eff ect on PUB rebleeding aft er successful endoscopic therapy of high-dose PPI vs. placebo, stratifi ed by SRH.
METHODS

Study population
Th e dataset for this study was from a large, double-blind, randomized, controlled, international clinical trial (NCT00251979), which was previously reported ( 16 ) . In brief, that study included PUB rebleeding rates aft er successful endoscopic hemostasis of patients with PUB stigmata (FIA, FIB, FIIA, and FIIB) who were treated with high-dose intravenous (IV) infusion of esomeprazole or placebo for 72 h in blinded manner and compared. Initial endoscopic hemostasis was with either monotherapies (injection of epinephrine, thermal coagulation, or hemoclipping) or combination therapies (epinephrine injection and thermal coagulation or hemoclipping), and was deemed successful before randomization onto this study. Post IV infusion of PPI vs. placebo of 72 h, all patients were treated with open label esomeprazole 40 mg per day from day 4 to day 30 in this study. PUB study patients were stratifi ed by Forrest classifi cation at baseline, including those with FIA, FIB, FIIA, and FIIB, which were all considered to be high risk for recurrent bleeding. Patients with oozing bleeding (FIB) lacked a visible vessel (FIIA) or adherent clot (FIIB). Patients with FIIC (fl at spots) or FIII (clean ulcer base) were excluded. One patient in the placebo group (total 389) was missing the Forrest classification and therefore was not included in this analysis (total 388 patients).
Outcomes of rebleeding with placebo and IV PPI
Clinically signifi cant rebleeding episodes were defi ned as recurrent hematemesis or melena, with a minimum decrease of 2 g of hemoglobin, and/or the need for transfusions of red blood cells, as detailed in the previous report ( 16 ) .
To exclude the potential infl uence of IV proton pump inhibitor (PPI) in this analysis and to evaluate the natural history aft er successful hemostasis, early PUB rebleeding rates up to 72 h in the placebo group were compared according to baseline SRH.
As another analysis for this report, the rates of PUB rebleeding up to 72 h on placebo vs. esomeprazole were also compared for patients according to their baseline SRH. Th is was to assess the potential benefi t of profound acid suppression aft er successful endoscopic hemostasis of FIB PUBs vs. other major SRH (FIA, FIIA and FIIB). We also assessed for potential interactions of SRH with type of treatment (PPI vs. placebo).
Hypothesis
Our hypotheses were that the rebleed rate of patients treated with placebo (no PPI) aft er successful endoscopic hemostasis of FIB PUBs would be signifi cantly lower than other major SRH (FIA, FIIA, FIIB) and that FIB patients would not benefi t clinically from high-dose IV PPI's.
Primary and secondary analyses
Both univariable and multivariable analyses were performed to determine independent risk factors for early rebleeding on IV placebo. We stratifi ed by FIB vs. other major SRH (FIA, FIIA, and FIIB) and analyzed both background characteristics and potential risk factors for rebleeding. Th e statistical testing performed was Fisher's exact test (with Bailey's method) for univariate analyses ( Table 1 ) and logistic regression for multivariable analyses ( Table 2 ) . For the multivariable analysis, variables with P <0.10 from the univariable analysis were included. Fisher's exact test was used for comparisons of treatment eff ects in Table 3 . A two-sided P -value<0.05 was considered to be a statistically signifi cant difference. Th e analyses were done using NMSP, a soft ware package validated against SAS proc LOGISTIC (Personal Communications Tore Persson, PhD).
RESULTS
Rebleeding in the placebo group according to endoscopic stigmata
For cumulative PUB rebleeding rates up to 72 h in the placebotreated group ( N =388) according to baseline SRH, refer to Figure 1 . Th ese are shown in decreasing order from highest to lowest rebleeding rates.
STOMACH
Rebleed Risk of Oozing PUBs
For a comparison of baseline demographic characteristics for FIB as the reference vs. other major SRH (FIA, FIIA, FIIB), refer to Table 1 . Th e two signifi cant diff erences at baseline on this univariable analysis were a higher rate of epinephrine injection alone for hemostasis and a higher rate of previous ulcer complications. Paradoxically, these diff erences might have been expected to increase rebleed risk of FIB patients, but that was not seen ( Figure 1 ) . Th e multivariable analysis with oozing as the reference SRH for early rebleeding are shown in Table 2 with the estimated odds ratios and confi dence intervals. Th ese are in descending order of odds ratios. All major SRH (FIA, FIIA, FIIB) had signifi cantly higher risks of rebleeding than FIB with odds ratios (and 95% confi dence intervals) increasing from 2.61 (1.05; 6.52) for FIIA (NBVV) to a high of 6.66 (2.19; 20.26) for FIA (spurting).
Rebleeding in the placebo vs. the high-dose esomeprazole groups
Th e comparisons of early PUB rebleeding rates within 72 h according to diff erent SRH and medical treatments (placebo vs. esomeprazole) are shown in Table 3 . As previously reported for the RCT, there was a signifi cantly lower rebleeding rate for all PUB patients treated with esomeprazole than placebo by 45% ( 16 ) . In the current analysis, all SRH groups except oozing (FIB) had a lower rate of PUB rebleeding with PPI than placebo. For the large FIB group of 329 patients (or 43% of all study patients), the rebleeding rates at 72 h were 5.4 % (9/166) for esomeprazole and 4.9% (8/163) for placebo treatment groups (Odds ratio 1.11, 95% CI −0.42-2.95).
In contrast, high-dose PPI reduced rebleeding rates at 72 h by 5.4% (FIIA) to 12.9% (FIIB) in comparison with placebo in each of the other major stigmata subgroups (FIA, FIIA, and FIIB) with the greatest reduction in clot (FIIB) PUBs. Th e NNT's were 8 for clot, 9 for spurting, and 19 for non-bleeding visible vessel. See Table 3 .
In the original RCT of 760 patients,( 16 ) the overall treatment eff ect of PPI vs. placebo for 72 h had an odds ratio of 0.55 (CI: −0.32 to 0.94). However, the eff ects of PPI on rebleeding were diluted by including the oozing patients, who had no apparent benefi t from PPI infusion. See Table 3 . If only the high-risk patients with major SRH (FIA, FIIA, FIIB) were included (431 patients), the treatment eff ect of PPI would have been greater with odds ratio of 0.41 (CI: −0.21 to 0.80). Similarly, the NNT would have been lower than it was with the large oozing group included −13 vs. 23- Table 3 . Th e implication of this reassessment is that, for a study of highrisk patients that excluded FIB (oozing) patients, there could have been a reduction in enrollment by more than 40%, with a resultant increase in overall treatment eff ect with odds ratio reduction from 0.55 to 0.41, and a reduction in the overall number needed to treat from 23 to 13 .
From the logistic regression model assessing treatment and stigmata eff ect, the overall treatment eff ect was signifi cant ( P =0.0237) as was the stigmata eff ect ( P =0.0415). However, the interaction between PPI treatment and individual stigmata was not significant ( P =0.3632) in this analysis. Th e PPI interaction with oozing compared with the other major SRH combined (FIA, FIIA, FIIB) was also evaluated and the P -value was lower but not signifi cant-P =0.097. Th e diff erence between the two P -values was mainly due to the small size of the FIA and FIIB groups, which makes the estimates of interaction uncertain there.
DISCUSSION
PUB patients with oozing bleeding (FIB) treated with IV placebo aft er successful endoscopic hemostasis had a signifi cantly reduced risk of rebleeding compared with other major SRH (FIA, FIIA, FIIB). When FIB as the reference group was compared with each of the other major SRH (FIA, FIIA, and FIIB) in a multivariable analysis of placebo-treated patients, all other major SRH had a signifi cantly higher risk of rebleeding. Th e odd ratios varied from 2.62 (NBVV-FIIA), to 4.12 (clot-FIIB), to 6.7 (spurt-FIA)- Table 2 .
Aft er successful endoscopic hemostasis in this study, patients with baseline major stigmata (FIA, FIIA, FIIB) had lower rebleeding rates with high-dose IV PPI's for 72 h than placebo-treated patients. In contrast, FIB (oozing) PUB patients on either IV placebo or high-dose PPI infusion displayed very low rebleeding rates. Th ese diff erences between post-hemostasis rebleeding rates with IV PPI or placebo indicate a clinically relevant reduction in rebleeding rates of 5.4 to 12.9% for each major stigmata except FIB. Th e original RCT was under powered to analyze treatment eff ect for individual SRH. However, the rebleeding rate for FIB aft er endoscopic hemostasis and placebo treatment was very low (4.9%), similar to FIB patients treated with PPI (5.4%). Since the rebleeding rates of FIB aft er endoscopic hemostasis were so low, it was unlikely that PPI could provide any additional clinical benefi t. Th e possible pathophysiologic reason why FIB PUBs might be less likely to rebleed aft er successful endoscopic hemostasis than other Forrest PUBs (FIA, FIIA, and FIIB) probably relates to smaller underlying arteries in FIB ulcers. Th e invisible arteries and their blood fl ow under SRH can now be detected by Doppler endoscopic probe ( 8, 17 ) . Recent endoscopic Doppler probe studies of patients with FIB PUBs vs. other major SRH have reported signifi cantly lower detection rates of underlying arterial fl ow than FIA, both before and aft er endoscopic treatment ( 8 ) . Specifi cally, the detection rate of arterial fl ow underlying for FIB PUBs before any endoscopic treatment was signifi cantly lower at 47% compared with FIA PUBs, which were 100% Doppler probe positive. Furthermore, aft er standard visually guided multipolar electrocoagulation (MPEC) or hemoclipping for ulcer hemostasis of these SRH, residual blood fl ow was detected by Doppler probe in 0% for FIB PUBs, but was still present in 35% of FIA PUBs. Most clinically relevant to explaining the current study results was that the rebleeding rate in this prospective study was signifi cantly lower for FIB than FIA (0 vs. 28.6%), in spite of the diff erent PPI therapy, which was high-dose IV PPI infusion for FIA patients vs. oral PPI for FIB patients aft er successful visually guided hemostasis ( 8 ) .
Other confi rmatory evidence that oozing (FIB) bleeding (not associated with a visible vessel or adherent clot) has a lower risk of rebleeding and emergency surgery than spurting (FIA) comes from past randomized controlled trials (RCT's) ( 6, 7 ) . Th e fi rst was a RCT of epinephrine injection vs. medical treatment alone of PUB patients with active bleeding, stratifi ed as FIA and FIB ( 6 ) . All patients with rebleeding had emergency surgery instead of repeat endoscopic hemostasis. For the medical groups (not treated endoscopically), rebleeding rates and surgical intervention in FIA were clinically much higher than the FIB patients −70% vs. 29%, respectively. A subsequent RCT by the same investigators compared epinephrine injection alone vs. combination epinephrine injection and heater probe coagulation for ulcer hemostasis of patients stratifi ed for by FIA or FIB PUBs ( 7 ). Th ere were signifi cantly higher rebleeding (22.2 vs. 6.5%) and emergency surgery rates (29.6 vs. 6.5%) in the FIA spurting arterial bleeding PUB patients treated with epinephrine alone vs. combination therapy. However, no signifi cant diff erences were seen between treatments for the much larger PUB group with FIB in whom rebleeding (6.5 vs. 2.9%) and emergency surgery rates (6.5 vs. 5.7%) were very low for the epinephrine group vs. the combination hemostasis group ( 7 ). Current guidelines now recommend that epinephrine cannot be used alone for hemostasis of PUBs with SRH ( 3, 4 ) .
Th ese cohort study and RCT results implied to the investigators that smaller blood vessels underlay oozing PUBs compared with other major SRH with spurting arterial bleeding or visible vessels (6) (7) (8) . Also, FIB PUBs were more easily and eff ectively treated with endoscopic hemostasis and had lower rebleeding rates either with medical treatment or with endoscopic hemostasis than PUBs with other major (FIA, FIIA, FIIB) SRH (6) (7) (8) (9) .
When PUBs are encountered by the endoscopist that have both oozing bleeding and either a visible vessel or adherent clot, Figure 1 . PUB rebleeding rates after endoscopic hemostasis, at 72 h in placebo-treated patients.
